ResMed (NYSE: RMD) reported Q4 EPS of $2.55, $0.07 better than the analyst estimate of $2.48. Revenue for the quarter came in at $1.3 billion versus the consensus estimate of $1.33 billion.

For earnings history and earnings-related data on ResMed (RMD) click here.